Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT06281769 Recruiting - Prostate Cancer Clinical Trials

Prostate Cancer Detection Rate of Targeted Biopsies With PCaVision

Start date: February 26, 2024
Phase: N/A
Study type: Interventional

The primary objective is to demonstrate non-inferiority of the detection rate of clinically significant prostate cancer (csPCa) in targeted biopsies based on PCaVision imaging (PCaVision pathway) in comparison with the detection rate of clinically significant cancer in targeted biopsies based on MRI (MRI pathway).

NCT ID: NCT06270043 Recruiting - Prostate Cancer Clinical Trials

Focal Therapy for Localized Prostate Cancer

Start date: February 1, 2024
Phase:
Study type: Observational [Patient Registry]

This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care.

NCT ID: NCT06262633 Recruiting - Prostate Cancer Clinical Trials

A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

This study is to investigate the efficacy of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.

NCT ID: NCT06259279 Recruiting - Prostate Cancer Clinical Trials

High Impact Training to Patients With Prostate Cancer and Bone Metastases

HIP
Start date: February 6, 2024
Phase: N/A
Study type: Interventional

HIP is a randomized controlled trial. The aim is investigate the effect, safety and feasibility of brief, high-impact exercise targeting bones in patients with prostate cancer and bone metastases. Furthermore, to investigate the effects of the intervention on bone status (bone mineral density) and body composition, physical function and performance, patient reported quality-of-life outcomes, falls and hospitalizations.

NCT ID: NCT06259123 Recruiting - Prostate Cancer Clinical Trials

Neoadjuvant PSMA-RLT in Oligometastatic PCa

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

Prospective single-center phase II study to evaluate the PSA, imaging and pathological response, as well as oncological outcomes of systemic radioligand therapy [177Lu]Lu-PSMAI&T (PSMA-RLT) in patients planned for radical prostatectomy (RP) for oligometastatic prostate cancer (PCa) diagnosed using [68Ga]Ga-PSMA-11 PET examination. Ten patients with oligometastatic primary PCa diagnosed using [68Ga]Ga-PSMA-11 PET-CT/MRI imaging will be included in this study.

NCT ID: NCT06257758 Recruiting - Breast Cancer Clinical Trials

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Start date: January 10, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers. There are two parts to this trial, part 1 and part 2. Part 1 of the trial aims to answer these questions: - The safety and tolerability of VIO-01 when it is given alone or in combination with other anti-cancer therapies. - The highest dose that people can take without having unacceptable side effects - How well your body tolerates the drug alone or in combination, how they are absorbed, and the effects they have on your disease. Part 2 of the trial will further test VIO-01's effect in participants with advanced HRRm or HRD+ solid tumors and HRRm/HRD+ recurrent ovarian cancer. Participants will follow a schedule of visits to the study site to have assessments done related to their health condition and to receive the trial treatment.

NCT ID: NCT06257264 Recruiting - Breast Cancer Clinical Trials

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Start date: February 28, 2024
Phase: Phase 1
Study type: Interventional

This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors. The study will also identify a recommended dose for expansion (RDFE) in subsequent disease directed studies. The study will be conducted in 2 parts: Part 1 (dose escalation and safety expansion) and Part 2 (dose expansion).

NCT ID: NCT06255041 Recruiting - Breast Cancer Clinical Trials

Detection of Cancer in Breath Samples by Trained Detection Dogs

Start date: February 10, 2021
Phase:
Study type: Observational

The goal of this study is to show that trained detection dogs can identify breast, lung, prostate or colorectal cancer by sniffing masks containing breath samples. In this study, individuals who will undergo cancer screening at an integrated cancer prevention center or biopsy for a suspected malignancy, will be asked to provide a breath sample by breathing into a surgical mask. The mask will then be sent to the laboratory, where trained detection dogs will determine if the person who provided the mask has breast, lung, prostate or colorectal cancer or if the person does not have these types of cancer. The results provided by the dogs will be compared to the actual cancer screening results or biopsy results in order to determine the accuracy of cancer detection by the trained dogs.

NCT ID: NCT06250751 Recruiting - Prostate Cancer Clinical Trials

Behavioral Exercise TRaining for Men Undergoing Androgen Depr Therapy for Prostate Ca

BETR-PC
Start date: February 5, 2024
Phase: N/A
Study type: Interventional

To refine a remote behavioral exercise training intervention for testing in a larger randomized trial.

NCT ID: NCT06238479 Recruiting - Prostate Cancer Clinical Trials

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Start date: March 5, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.